Open-label Clinical Study to Assess the Safety and Adequacy of Effectiveness of the SpectraCure P18 System (Interstitial Multiple Diode Lasers and IDOSE® Software) and Verteporfin for Injection (VFI) for the Treatment of Recurrent Prostate Cancer
The rationale for the study is to obtain safety data as well as to establish dose parameters
for the SpectraCure P18 System with IDOSE®, with verteporfin for injection (VFI) as
photosensitizer for the treatment of recurrent prostate cancer.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society